Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:
Rarely before has a large-cap biotech had so much riding on the outcome of a Phase 2 study as Amgen does with its obesity treatment MariTide, also known as AMG 133. Results are coming before the end of the year.
Novo Nordisk will report results of a Phase 3 study involving its obesity drug candidate CagriSema before the end of this year. CagriSema is a combination of the GLP-1 drug semaglutide, the active ingredient in Ozempic and Wegovy, and cagrilintide, a treatment that activates amylin and calcitonin receptors.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in